FDA Approves Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
RegulatoryapprovedAtebriozPositive
AI Analysis
Summary
Mirum Pharmaceuticals and Incyte announced FDA approval of Atebrioz (zilurgisertib) for adult and pediatric patients with Fibrodysplasia Ossificans Progressiva. This marks a significant regulatory milestone for a rare genetic disorder.
Outcome Details
FDA approval for adult and pediatric patients with Fibrodysplasia Ossificans Progressiva
Importance:9/10
Sentiment:
1.00
FDA approvalrare diseasepediatric indication
Read the original article
Published by Drugs.com New Drug Approvals on September 25, 2026 2:09 AM